Business Context and Reporting Period
This Form 8-K is filed by Healthcare Triangle, Inc. (HCTI), a Delaware corporation listed on The Nasdaq Stock Market LLC. The report covers events occurring on July 28, 2026, with the filing date of July 29, 2026. The Company is designated as an emerging growth company.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on the issuance of unregistered equity securities.
Material Changes
The primary material change reported is a significant increase in the Company's outstanding common stock due to two separate transactions closed on July 28, 2026:
- Teyame Acquisition: Issued 9,718,373 shares of common stock to eight entities at the direction of Teyame AI LLC in connection with the closing of the Teyame Transaction.
- SecureKloud Securities Exchange: Issued 2,828,167 shares of common stock to one individual and one entity pursuant to a Securities Exchange Agreement with SecureKloud Technologies Ltd.
- Total Issuance: An aggregate of 12,546,540 shares of common stock (par value $0.00001) was issued on this date.
Both issuances were approved by shareholders at the Annual Meeting on July 17, 2026, and relied on exemptions from registration under Section 4(a)(2) of the Securities Act and/or Regulation D. No underwriters were involved, and no commissions were paid.
Guidance, Outlook, and Risks
The filing includes a Regulation FD Disclosure (Item 7.01) referencing a press release issued on July 29, 2026, regarding the share issuances. The text of the press release is attached as Exhibit 99.1 but is not deemed "filed" for purposes of Section 18 of the Exchange Act unless specifically incorporated by reference. The filing does not provide specific forward-looking guidance, management commentary on future operations, or detailed risk factors beyond the standard disclosure regarding the unregistered nature of the securities.
Investor Verification Checklist
- Verify the impact of the 12,546,540 new shares on existing shareholder dilution.
- Review the attached Exhibit 99.1 (Pricing Press Release) for details on the valuation and terms of the Teyame and SecureKloud transactions.
- Confirm the status of the Teyame Transaction and the SecureKloud Securities Exchange Agreement to understand the strategic rationale behind these equity issuances.
- Check subsequent filings for any updated capitalization tables reflecting the new share count.